Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26199219 | 1.00 | OPRD1 (0.69) | OPRD1CHRM2CHRM1SLC6A2SLC6A4 | |
| SCHEMBL20832766 | 0.86 | SLC6A2 (0.56) | OPRD1SLC6A2SLC6A4SLC6A3OGA | |
| SCHEMBL22227819 | 0.86 | SLC6A2 (0.56) | OPRD1SLC6A2SLC6A4SLC6A3OGA | |
| SCHEMBL26199245 | 0.84 | MC4R (0.54) | OPRD1CHRM2CHRM1SLC6A2SLC6A4 | |
| SCHEMBL25168549 | 0.83 | OPRD1 (0.66) | OPRD1CHRM2CHRM1OGAOPRM1 | |
| SCHEMBL5857482 | 0.83 | CHRM2 (0.55) | OPRD1CHRM2CHRM1OPRM1 | |
| SCHEMBL25168550 | 0.83 | OPRD1 (0.66) | OPRD1CHRM2CHRM1OGAOPRM1 | |
| SCHEMBL13267271 | 0.82 | ALDH1A1 (0.58) | OPRD1SLC6A2SLC6A4SLC6A3OGA | |
| SCHEMBL25168575 | 0.82 | ALDH1A1 (0.58) | OPRD1SLC6A2SLC6A4SLC6A3OGA | |
| SCHEMBL13380743 | 0.82 | OPRD1 (0.65) | OPRD1CHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115776983-A | Heterocyclic immunomodulators | 北京诺诚健华医药科技有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-113896711-A | Heterocyclic immunomodulators | 北京诺诚健华医药科技有限公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-2509973-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | Arch Pharmalabs Limited (IN) | 2012-10-17 | — | — | EP | disclosed |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | SHANGHAI PARLING PHARMATECH CO., LTD. (CN) | 2011-12-15 | — | — | US | disclosed |
| WO-2011070588-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ARCH PHARMALABS LIMITED (IN) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ABL1, JAK2, ABL2 | OPRD1 4267/4885CHRM2 4832/4885CHRM1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.